Lidocaine injection is on backorder because multiple manufacturers are simultaneously experiencing production problems and a surge in demand they can’t keep up with. This isn’t a single-supplier issue. At least three major manufacturers have reported shortages at the same time, creating a ripple effect across hospitals, dental offices, and pharmacies nationwide.
What’s Causing the Shortage
The shortage traces back to two overlapping problems: rising demand and manufacturing setbacks. According to the American Society of Health-System Pharmacists (ASHP), which tracks drug shortages in real time, each major supplier has cited its own combination of factors.
Amphastar, which produces lidocaine in prefilled syringes, reported shortages driven by increased demand. Eugia, another key supplier, cited the same reason. Pfizer’s situation is more complicated, with both manufacturing delays and increased demand affecting its lidocaine products. When one manufacturer falls behind, healthcare facilities turn to the remaining suppliers, which only accelerates the demand problem for everyone else.
Lidocaine is one of the most widely used local anesthetics in medicine. It’s the go-to numbing agent for everything from stitching up a cut in the emergency room to dental procedures to heart rhythm emergencies. That broad use means even a modest production dip creates shortages quickly, because there’s no single clinical setting that can simply stop using it.
Why Multiple Manufacturers Are Affected
Injectable medications are harder to produce than pills. They require sterile manufacturing environments, specialized equipment, and strict quality testing at every step. When a production line goes down for maintenance, upgrades, or quality control issues, it can take weeks or months to restart. Unlike a tablet factory that might ramp up output relatively quickly, sterile injectable facilities operate under tighter constraints.
The lidocaine market also has a limited number of producers. With only a handful of companies making injectable formulations, the loss of even one supplier’s output shifts enormous pressure onto the others. This concentrated supply chain is a recurring vulnerability for generic injectable drugs in general, not just lidocaine.
Which Formulations Are Hardest to Find
Not all lidocaine products are equally affected. The shortage primarily involves injectable forms: vials, prefilled syringes, and ampules used in hospitals and clinical settings. Topical lidocaine products (creams, patches, gels) operate through different supply chains and are generally still available, though spot shortages can occur when facilities try to substitute topical forms for some uses.
Prefilled syringes have been particularly hard to source, since fewer manufacturers produce them compared to standard vials. These ready-to-use syringes are popular in emergency departments and operating rooms because they save preparation time, so their absence creates workflow disruptions on top of the supply gap.
How Hospitals Are Responding
Healthcare facilities have adopted several strategies to stretch limited supplies. Many hospitals now restrict lidocaine use to situations where it’s most critical, prioritizing emergency cardiac care and essential procedures over elective uses. Some have shifted to alternative local anesthetics like bupivacaine or mepivacaine where clinically appropriate, though these substitutes aren’t interchangeable in every scenario.
Intravenous lidocaine has also grown in popularity as a pain management tool during and after surgery. A survey of Scottish hospitals found that 75% either use or plan to use IV lidocaine for acute pain management, which adds another source of demand on top of its traditional uses. Hospitals that had expanded lidocaine’s role in pain control are now reconsidering which patients truly need it and which can be managed with other approaches.
The FDA has also enabled a workaround through compounding pharmacies. Under section 503B of federal law, outsourcing facilities can compound lidocaine preparations when the drug appears on the official shortage list. This allows specialty pharmacies to produce lidocaine injections to partially fill the gap, though compounded products can’t fully replace the volume that major manufacturers supply.
When Supply Might Recover
Drug shortages involving injectable generics are notoriously difficult to predict. Manufacturers rarely provide firm resolution dates, and the ASHP shortage listings for lidocaine currently reflect ongoing supply constraints without specific recovery timelines. Historically, injectable drug shortages of this type can last anywhere from several months to over a year, depending on how quickly manufacturers resolve production issues and whether demand stabilizes.
If you’re a patient with an upcoming procedure, the shortage is unlikely to cause a cancellation. Hospitals maintain emergency reserves, and clinicians have alternative anesthetics available. You may simply receive a different numbing agent than you’d otherwise get, or your provider may use a different concentration or packaging than usual. The practical impact is felt more acutely by the pharmacists and supply chain managers working behind the scenes to keep essential medications available.